par Piccart-Gebhart, Martine ;Lohrisch, C;Di Leo, Angelo ;Larsimont, Denis
Référence Oncology, 61 Suppl 2, page (73-82)
Publication Publié, 2001
Référence Oncology, 61 Suppl 2, page (73-82)
Publication Publié, 2001
Article révisé par les pairs
Titre: |
|
Auteur: | Piccart-Gebhart, Martine; Lohrisch, C; Di Leo, Angelo; Larsimont, Denis |
Informations sur la publication: | Oncology, 61 Suppl 2, page (73-82) |
Statut de publication: | Publié, 2001 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Algorithms |
Antibiotics, Antineoplastic -- administration & dosage | |
Antibodies, Monoclonal -- administration & dosage | |
Antibodies, Monoclonal -- therapeutic use | |
Antineoplastic Agents -- therapeutic use | |
Antineoplastic Agents, Hormonal -- contraindications | |
Antineoplastic Agents, Hormonal -- therapeutic use | |
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
Breast Neoplasms -- chemistry | |
Breast Neoplasms -- genetics | |
Breast Neoplasms -- mortality | |
Chemotherapy, Adjuvant | |
Clinical Trials as Topic | |
Disease Progression | |
Drug Resistance, Multiple | |
Drug Resistance, Neoplasm | |
Female | |
Genes, erbB-2 | |
Humans | |
Neoplasm Metastasis | |
Neoplasm Proteins -- analysis | |
Neoplasm Proteins -- genetics | |
Predictive Value of Tests | |
Prospective Studies | |
Randomized Controlled Trials as Topic | |
Receptor, erbB-2 -- analysis | |
Receptors, Estrogen -- analysis | |
Retrospective Studies | |
Risk | |
Survival Analysis | |
Tamoxifen -- contraindications | |
Tamoxifen -- therapeutic use | |
Treatment Outcome | |
Tumor Markers, Biological -- analysis | |
Tumor Markers, Biological -- genetics | |
Note générale: | Comparative Study |
Journal Article | |
Review | |
Langue: | Anglais |
Identificateurs: | urn:issn:0030-2414 |
info:pii/ocl1b073 | |
info:pmid/11694791 |